会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明公开
    • CORNEAL STROMAL KERATOCYTE CULTURE
    • HORNHAUT - 间质KERATOZYTENKULTUR
    • EP3047018A1
    • 2016-07-27
    • EP14845539.7
    • 2014-09-17
    • Singapore Health Services Pte Ltd
    • YAM, Hin-Fai, GaryMEHTA, Jodhbir
    • C12N5/071C12N5/02
    • C12N5/0621C12N2500/84C12N2501/105C12N2501/727C12N2502/025C12N2533/54
    • The present invention relates to corneal stromal keratocytes (CSKs) culture. In particular the present invention relates to a method for culturing corneal stromal keratocytes ex vivo. The method utilises a dual culture medium protocol. In the presence of serum (in particular low serum concentration) in a first culture medium A, the "activated keratoctyes" are expandable while specific CSK gene expression is maintained in serum-free ERI condition in a second culture medium B. The invention also relates to culture medium A and B which is supplemented with liquid amnion extract or other additional supplements. This protocol also applied to CSK from other species. Additionally, the present invention provides method for CSK cultivation to provide sufficient quantity of genuine CSKs for corneal tissue engineering without a risk of fibroblastic changes.
    • 本发明涉及角膜基质角化细胞(CSKs)培养。 特别地,本发明涉及离体培养角膜基质角膜细胞的方法。 该方法采用双重培养基方案。 在第一培养基A中存在血清(特别是低血清浓度)的情况下,第二培养基B中“活化的角质细胞”是可扩展的,而特异性CSK基因表达维持在无血清ERI条件下。本发明还涉及 到补充有液体羊膜提取物或其他补充剂的培养基A和B。 该协议也适用于其他物种的CSK。 另外,本发明提供了CSK培养方法,以提供足够数量的用于角膜组织工程的真正的CSK,而没有成纤维细胞变化的风险。